|1.||Stone, Gregg W: 65 articles (04/2015 - 09/2003)|
|2.||Mehran, Roxana: 54 articles (02/2015 - 09/2003)|
|3.||Lim, Kye-Taek: 46 articles (05/2014 - 12/2004)|
|4.||Harrington, Robert A: 43 articles (05/2015 - 01/2002)|
|5.||Feldmann, Heinz: 42 articles (10/2015 - 01/2003)|
|6.||White, Harvey D: 37 articles (05/2015 - 06/2002)|
|7.||Topol, E J: 37 articles (10/2003 - 01/2000)|
|8.||Califf, Robert M: 34 articles (04/2014 - 01/2002)|
|9.||Ohman, E Magnus: 33 articles (03/2015 - 08/2002)|
|10.||Gibson, C Michael: 30 articles (03/2015 - 11/2002)|
08/01/1997 - "A trial vaccine containing pseudorabies virus (PRV) glycoprotein gC as the main component showed excellent protection against virulent virus infection in pigs. "
12/01/2015 - "Glycoproteins of human milk are multifunctional molecules, and their fucosylated variants are potentially active molecules in immunological events ensuring breastfed infants optimal development and protection against infection diseases. "
06/01/1990 - "Antibody mediated and cell mediated immune responses to the envelope glycoproteins gp120 and gp41 of the human immunodeficiency virus (HIV-1) are considered important for protection against infection and for attenuation of disease symptoms after infection. "
12/15/2005 - "In recent clinical trials, a vaccine that contained herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) and the adjuvant AS04 afforded HSV-seronegative women significant protection against HSV-2 genital disease and limited protection against infection. "
11/01/2008 - "colubriformis glycoprotein Tc-120 and CarLA were tested in the passive immunity model and it was found that only the antibody against CarLA resulted in a significant reduction of infection (87%). "
07/15/2014 - "Efficacy of pre-hospital use of glycoprotein IIb/IIIa inhibitors in ST-segment elevation myocardial infarction before mechanical reperfusion in a rapid-transfer network (from the Acute Myocardial Infarction Registry of Brittany)."
12/15/2012 - "We investigated whether additional platelet inhibition with a glycoprotein IIb/IIIa inhibitor would be beneficial in reducing the risk of periprocedural myocardial infarction (PMI) in diabetic patients with high residual platelet reactivity (HPR). "
04/01/2009 - "Several clinical trials have shown that antagonists of the glycoprotein IIb/IIIa receptor decreased the incidence of death, nonfatal myocardial infarction, and the need for urgent revascularization when administered immediately before or during the 24- to 48-hour period after percutaneous coronary intervention (PCI). "
09/16/2003 - "Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. "
06/15/2013 - "Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction."
|3.||Acute Coronary Syndrome
09/01/2011 - "Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials. "
06/01/2004 - "Potent inhibition of the platelet glycoprotein IIb/IIIa receptor has improved the acute outcome of patients presenting with acute coronary syndromes (ACS). "
01/01/1999 - "The results of different clinical studies show evidence that glycoprotein IIb-IIIa antagonists, given intravenously, are effective in the management of acute coronary intervention with high thrombogenic risk, and also help to control the early phase of acute coronary syndromes. "
09/15/2004 - "Although the efficacy of glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndromes is greatest in patients who undergo percutaneous coronary intervention (PCI), it was hypothesized that high-risk patients managed without PCI also benefit. "
07/11/2000 - "Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. "
01/01/1979 - "Administration of this glycoprotein has resulted in significant reduction of tumor mass in more than half of all patients treated up to this time."
04/01/1999 - "The vvE13 recombinant vaccinia virus expressing the HIV-1 envelope glycoprotein gp120 fused to a non-cleavable transmembrane protein elicits superior protection against tumors expressing the gp160 envelope glycoprotein, as compared to vvE1 expressing gp160."
02/01/1994 - "In addition, DHE was slightly more effective in purging tumor cells expressing the p-170 glycoprotein.(ABSTRACT TRUNCATED AT 250 WORDS)"
02/01/1993 - "In addition, DHE was slightly more effective in purging tumor cells expressing the p-170 glycoprotein. "
07/15/2014 - "This work demonstrates the feasibility of employing SNA-I to selectively recognize the STn epitope in glycoproteins and the use of the constructed biosensor was effective in the analysis of serum samples with the ability to discriminate in a fast way between cancer and healthy status. "
05/01/2011 - "Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. "
07/01/2006 - "Although glycoprotein IIb/IIIa inhibitors appear to be beneficial in select cases, bleeding concerns exist. "
08/01/1999 - "The concomitant intravenous administration of a glycoprotein IIb/IIIa receptor antagonist (in combination with a reduced dose of a fibrinolytic) appears to be able to further enhance the efficacy for clot lysis without increasing the risk for bleeding complications."
07/01/2011 - "Our model for evaluating the risk of non-CABG-related major bleeding in patients undergoing elective PCI identified sex, the type of antithrombin used, and glycoprotein IIb/IIIa inhibitor use as important indicators of bleeding risk, and accurately predicted the incidence of non-CABG-related major bleeding in patients undergoing elective PCI in the STEEPLE trial."
01/01/2008 - "While awaiting the results of a few other currently ongoing trials, facilitated PCI should now probably be restricted to the administration of glycoprotein IIb-IIIa inhibitors for patients at high risk of cardiovascular events and at low risk of bleeding when a more than 60-minute delay to primary PCI is anticipated. "
|2.||Platelet Membrane Glycoprotein IIb
|2.||Angioplasty (Angioplasty, Transluminal)
|3.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)